UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-41316
Alpha Tau Medical Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Kiryat HaMada St. 5
Jerusalem, Israel 9777605
+972 (3) 577-4115
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On June 23, 2026, Alpha Tau Medical Ltd. (the “Company”) held its Annual General Meeting of Shareholders (the “Meeting”) at the Company’s headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel.
At the Meeting, the Company’s shareholders approved the following proposals:
| (1) | To re-elect each of David Milch and Ruth Alon as Class II directors, to hold office until the close of the Company’s Annual General Meeting of Shareholders in 2029, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Amended and Restated Articles of Association or the Companies Law 5759-1999 (the “Companies Law”); | |
| (2) | To re-approve the Company’s Compensation Policy for Executive Officers and Directors; | |
| (3) | To approve the re-appointment of Uzi Sofer, our Chief Executive Officer, to continue serving as Chairman of the board of directors of the Company (the “Board”); | |
| (4) | To approve a compensation package for Uzi Sofer, our Chief Executive Officer and Chairman; | |
| (5) | To approve the extension of terms of certain options for directors and officers of the Company; and | |
| (6) | To approve the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and until the Company’s next annual general meeting of shareholders, and to authorize the Board (with power of delegation to its audit committee) to set the fees to be paid to such auditors. |
All proposals were approved at the Meeting by the respective requisite majorities in accordance with the Companies Law, and the Company’s Amended and Restated Articles of Association, as described in the Proxy Statement which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission on May 18, 2026.
This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-274457, 333-288240 and 333-295359) and Form S-8 (File Nos. 333-264169, 333-270406, 333-277733, 333-285745 and 333-294151).
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Alpha Tau Medical Ltd. | ||
| Date: June 25, 2026 | By: | /s/ Uzi Sofer |
| Uzi Sofer | ||
| Chief Executive Officer | ||
2